AbbVie Inc (ABBV)vsArtivion Inc (AORT)
ABBV
AbbVie Inc
$227.23
-2.14%
HEALTHCARE · Cap: $391.50B
AORT
Artivion Inc
$20.12
-3.45%
HEALTHCARE · Cap: $971.11M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 13595% more annual revenue ($62.82B vs $458.69M). ABBV leads profitability with a 5.8% profit margin vs 2.5%. ABBV appears more attractively valued with a PEG of 0.61. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AORT
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Margin of Safety
-31.9%
Fair Value
$30.41
Current Price
$20.12
$10.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
17.5% revenue growth
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 80.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while AORT is a growth play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.26 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 41/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?